Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-02-13
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech combining automated wet-lab experimentation and machine learning to advance internal drug candidates and partner discovery programs.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof-to-product is the whole game by 2031
A base-case multi-year re-rate is plausible if early human signals convert into a registrational plan and partner economics shift toward outcome-based, royalty-like capture. The bear case remains a long platform winter driven by failed translation, lumpy services revenue, and dilution.

Analysis

Thesis
RXRX’s non-linear upside is a re-rating from “AI platform story” to “evidence-to-asset factory”: if it converts early human signals into FDA-aligned late-stage plans and packages its platform as verified, outcome-priced decisions (not tools), it can monetize proprietary data + closed-loop throughput in a world where generic cognition gets cheap.
Last Economy Alignment
As AI commoditizes analysis, RXRX’s scarcity is owned experimental evidence, data rights, and an integrated atoms+bits loop; value capture should shift toward verified decisions, milestones, and royalties. Alignment is capped by clinical/regulatory gating and services-like pricing fragility if partners in-source.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.8x (from 5 most recent analyses)
Reasoning
By 2031, RXRX can plausibly earn meaningful revenue from a hybrid mix: (1) early product/near-commercial economics in a focused rare-disease niche, (2) milestone/royalty-bearing partner progress, and (3) higher-quality platform revenue if it standardizes deliverables into outcome-priced “pods” with provenance/audit attachments. The multiple expands if revenue becomes less services-like and more contractual/royalty-like, while cash discipline reduces forced-financing overhang.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding constraint is repeatable clinical and regulatory proof: without it, platform monetization stays lumpy and compressible. Second-order risks are financing/dilution from sustained burn, governance/control remediation timelines, and competitive convergence as pharma builds internal AI+automation stacks.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$9.40
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case